{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T06:14:24Z","timestamp":1758608064984,"version":"3.44.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clml.2025.05.024","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T20:33:32Z","timestamp":1748723612000},"page":"e799-e808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasmablastic Lymphoma\u2014A Crosstalk Between Myeloma and Lymphoma"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8066-4584","authenticated-orcid":false,"given":"Maha","family":"Hameed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Iftikhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakina","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zohaa","family":"Faiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fathima Shehnaz","family":"Ayoobkhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Affan","family":"Elahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaista","family":"Khadim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Husnain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.05.024_bib0001","first-page":"1413","article-title":"Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection","volume":"89","author":"Delecluse","year":"1997","journal-title":"Blood J Am Soci Hematol"},{"issue":"15","key":"10.1016\/j.clml.2025.05.024_bib0002","first-page":"2323","article-title":"The biology and treatment of plasmablastic lymphoma","volume":"125","author":"Castillo","year":"2015","journal-title":"Blood J Am Soc Hematol"},{"key":"10.1016\/j.clml.2025.05.024_bib0003","first-page":"511","article-title":"Plasmablastic lymphoma: case report","volume":"58","author":"Olvera-Acevedo","year":"2020","journal-title":"Revista Medica del Instituto Mexicano del Seguro Social."},{"key":"10.1016\/j.clml.2025.05.024_bib0004","series-title":"StatPearls","article-title":"Plasmablastic lymphoma","author":"Bhatt","year":"2024"},{"issue":"7","key":"10.1016\/j.clml.2025.05.024_bib0005","first-page":"1720","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.05.024_bib0006","first-page":"875","article-title":"Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases","volume":"38","author":"Morscio","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1016\/j.clml.2025.05.024_bib0007","first-page":"1571","article-title":"Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review","volume":"35","author":"Liu","year":"2011","journal-title":"Leuke Res"},{"key":"10.1016\/j.clml.2025.05.024_bib0008","first-page":"392","article-title":"AIDS-related non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment","volume":"33","author":"Carbone","year":"2002","journal-title":"Human Pathol"},{"issue":"4","key":"10.1016\/j.clml.2025.05.024_bib0009","first-page":"843","article-title":"Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group","volume":"28","author":"Tchernonog","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.05.024_bib0010","first-page":"54","article-title":"Plasmablastic lymphoma: an update","volume":"44","author":"Bailly","year":"2022","journal-title":"Int J Laborat Hematol"},{"key":"10.1016\/j.clml.2025.05.024_bib0011","first-page":"e219","article-title":"Clinicopathologic characterization of children with B-cell non-hodgkin lymphoma over 10 years at a tertiary center in Cape Town, South Africa","volume":"42","author":"Kriel","year":"2020","journal-title":"J Pediatr Hematol\/Oncol."},{"key":"10.1016\/j.clml.2025.05.024_bib0012","first-page":"2047","article-title":"Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma","volume":"51","author":"Castillo","year":"2010","journal-title":"Leuke Lymph"},{"issue":"1","key":"10.1016\/j.clml.2025.05.024_bib0013","first-page":"54","article-title":"Plasmablastic lymphoma: an update","volume":"44","author":"Bailly","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.clml.2025.05.024_bib0014","first-page":"1723","article-title":"Immunology of EBV-related lymphoproliferative disease in HIV-positive individuals","volume":"10","author":"Shindiapina","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2025.05.024_bib0015","first-page":"40","article-title":"Epstein\u2013Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: a review","volume":"52","author":"Marques-Piubelli","year":"2020","journal-title":"Pathology"},{"key":"10.1016\/j.clml.2025.05.024_bib0016","first-page":"265","article-title":"Epstein\u2013Barr virus-associated malignancies: roles of viral oncoproteins in carcinogenesis","volume":"8","author":"El-Sharkawy","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2025.05.024_bib0017","first-page":"976","article-title":"Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients","volume":"101","author":"Laurent","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.05.024_bib0018","article-title":"EBV infection determines the immune hallmarks of plasmablastic lymphoma","volume":"7","author":"Gravelle","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clml.2025.05.024_bib0019","first-page":"1120","article-title":"Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma","volume":"106","author":"Garcia-Reyero","year":"2021","journal-title":"Haematologica"},{"volume":"2","year":"2008","author":"Campo","key":"10.1016\/j.clml.2025.05.024_bib0020"},{"key":"10.1016\/j.clml.2025.05.024_bib0021","first-page":"6","article-title":"Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues","volume":"38","author":"Grimm","year":"2019","journal-title":"Ann Diagnost Pathol"},{"key":"10.1016\/j.clml.2025.05.024_bib0022","first-page":"23","article-title":"The genomic landscape of HIV-associated plasmablastic lymphoma","volume":"1","author":"K\u00fcppers","year":"2020","journal-title":"Blood Cancer Disc"},{"key":"10.1016\/j.clml.2025.05.024_bib0023","first-page":"370","article-title":"Plasmablastic lymphomas show restricted EBV latency profile and MYC gene aberrations","volume":"63","author":"Ramburan","year":"2022","journal-title":"Leuke Lymph"},{"key":"10.1016\/j.clml.2025.05.024_bib0024","first-page":"61","article-title":"Lymphoid neoplasms with plasmablastic differentiation: a comprehensive review and diagnostic approaches","volume":"27","author":"Chen","year":"2020","journal-title":"Adv Anatom Pathol"},{"key":"10.1016\/j.clml.2025.05.024_bib0025","first-page":"5546","article-title":"c-Myc and cancer metabolism","volume":"18","author":"Miller","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2025.05.024_bib0026","first-page":"86","article-title":"MYC status in HIV-associated plasmablastic lymphoma: dual-colour CISH, FISH and immunohistochemistry","volume":"79","author":"Pather","year":"2021","journal-title":"Histopathology."},{"key":"10.1016\/j.clml.2025.05.024_bib0027","first-page":"2682","article-title":"MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma","volume":"106","author":"Ramis-Zaldivar","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.05.024_bib0028","first-page":"488","article-title":"Double-hit plasmablastic lymphoma with malignant pleural effusion and leukaemic presentation","volume":"52","author":"Huang","year":"2020","journal-title":"Pathology"},{"key":"10.1016\/j.clml.2025.05.024_bib0029","first-page":"5183","article-title":"Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma","volume":"12","author":"Frontzek","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2025.05.024_bib0030","first-page":"53","article-title":"Diffuse large B-cell lymphoma variants: an update","volume":"52","author":"Sukswai","year":"2020","journal-title":"Pathology"},{"key":"10.1016\/j.clml.2025.05.024_bib0031","first-page":"736","article-title":"Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities","volume":"28","author":"Colomo","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2025.05.024_bib0032","first-page":"991","article-title":"Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features","volume":"23","author":"Taddesse-Heath","year":"2010","journal-title":"Modern Pathol"},{"key":"10.1016\/j.clml.2025.05.024_bib0033","first-page":"1074","article-title":"Plasmablastic lymphoma: a review of clinicopathologic features and differential diagnosis","volume":"140","author":"Harmon","year":"2016","journal-title":"Arch Pathol Laborat Med"},{"issue":"3","key":"10.1016\/j.clml.2025.05.024_bib0034","first-page":"139","article-title":"Cytologic features of plasmablastic lymphoma: report of four cases","volume":"105","author":"Lin","year":"2005","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.clml.2025.05.024_bib0035","first-page":"1342","article-title":"Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype","volume":"95","author":"Montes-Moreno","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.05.024_bib0036","first-page":"775","article-title":"Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma","volume":"70","author":"Ahn","year":"2017","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.clml.2025.05.024_bib0037","first-page":"61","article-title":"Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytometry Part B: Clin Cytometry"},{"key":"10.1016\/j.clml.2025.05.024_bib0038","first-page":"38","article-title":"Plasmablastic lymphoma: a review","volume":"15","author":"Rafaniello Raviele","year":"2009","journal-title":"Oral Diseases"},{"key":"10.1016\/j.clml.2025.05.024_bib0039","series-title":"Novel Therapeutics For Rare Lymphomas","first-page":"101","article-title":"Plasmablastic lymphoma and primary effusion lymphoma","author":"Guerrero-Garcia","year":"2020"},{"issue":"2","key":"10.1016\/j.clml.2025.05.024_bib0040","first-page":"61","article-title":"Lymphoid neoplasms with plasmablastic differentiation: a comprehensive review and diagnostic approaches","volume":"27","author":"Chen","year":"2020","journal-title":"Adv Anatom Pathol"},{"key":"10.1016\/j.clml.2025.05.024_bib0041","first-page":"54","article-title":"Plasmablastic lymphoma: an update","volume":"44","author":"Bailly","year":"2022","journal-title":"Int J Laborat Hematol"},{"key":"10.1016\/j.clml.2025.05.024_bib0042","first-page":"2845","article-title":"Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK\u2009+\u2009LBCL): a systematic review of clinicopathological features and management","volume":"62","author":"Castillo","year":"2021","journal-title":"Leuke Lymph"},{"key":"10.1016\/j.clml.2025.05.024_bib0043","first-page":"381","article-title":"ALK-positive large B-cell lymphomas: a clinicopathologic study","volume":"65","author":"Chandramohan","year":"2022","journal-title":"Indian J Pathol Microbiol"},{"year":"2014","series-title":"Robbins and Cotran Pathologic Basis of Disease","author":"Kumar","key":"10.1016\/j.clml.2025.05.024_bib0044"},{"key":"10.1016\/j.clml.2025.05.024_bib0045","first-page":"5270","article-title":"Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy","volume":"118","author":"Castillo","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.05.024_bib0046","first-page":"423","article-title":"Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy","volume":"43","author":"Nasta","year":"2002","journal-title":"Leuke Lymph"},{"key":"10.1016\/j.clml.2025.05.024_bib0047","first-page":"1361","article-title":"Spontaneous regression of an HIV-associated plasmablastic lymphoma in the oral cavity: a case report","volume":"65","author":"Armstrong","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.clml.2025.05.024_bib0048","article-title":"Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma","volume":"12","author":"Candelaria","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2025.05.024_bib0049","article-title":"Plasmablastic lymphoma: current knowledge and future directions","volume":"15","author":"Li","year":"2024","journal-title":"Front Immun"},{"key":"10.1016\/j.clml.2025.05.024_bib0050","first-page":"e255","article-title":"The emerging treatment options of plasmablastic lymphoma: analysis of 173 individual patient outcomes","volume":"21","author":"Makady","year":"2021","journal-title":"Clin Lymph Myel Leuke"},{"key":"10.1016\/j.clml.2025.05.024_bib0051","first-page":"3251","article-title":"Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients","volume":"122","author":"Barta","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.05.024_bib0052","first-page":"2121","article-title":"Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis","volume":"59","author":"Dittus","year":"2018","journal-title":"Leuke Lymph"},{"key":"10.1016\/j.clml.2025.05.024_bib0053","first-page":"1580","article-title":"Use of Bortezomib-containing regimens in the frontline treatment of patients with plasmablastic lymphoma: a multicenter retrospective analysis","volume":"130","author":"Guerrero","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.05.024_bib0054","first-page":"679","article-title":"Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma","volume":"184","author":"Castillo","year":"2019","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2025.05.024_bib0055","article-title":"BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma","volume":"11","author":"Raghunandan","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.clml.2025.05.024_bib0056","first-page":"E28","article-title":"Axicabtagene ciloleucel for CD19+ plasmablastic lymphoma","volume":"95","author":"Raychaudhuri","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.05.024_bib0057","first-page":"7","article-title":"A meta-analysis of highly active anti-retroviral therapy for treatment of plasmablastic lymphoma","volume":"3","author":"Guan","year":"2010","journal-title":"Hematol\/Oncol Stem Cell Ther"},{"key":"10.1016\/j.clml.2025.05.024_bib0058","first-page":"5003","article-title":"Incorporating bortezomib in the management of plasmablastic lymphoma","volume":"39","author":"Umeanaeto","year":"2019","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.clml.2025.05.024_bib0059","first-page":"112","article-title":"Bortezomib-and lenalidomide-based treatment of refractory plasmablastic lymphoma","volume":"43","author":"Ando","year":"2020","journal-title":"Oncol Res Treatment"},{"key":"10.1016\/j.clml.2025.05.024_bib0060","first-page":"4573","article-title":"Daratumumab plus chemotherapy induces complete responses in a consecutive series of four patients with plasmablastic lymphoma","volume":"138","author":"Ricker","year":"2021","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2025.05.024_bib0061","first-page":"4928","article-title":"Targeting CD38 with Daratumumab Plus Chemotherapy for patients with advanced-stage plasmablastoid large B-cell lymphoma","volume":"11","author":"Ryu","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.clml.2025.05.024_bib0062","first-page":"S275","article-title":"ABCL-407: daratumumab, lenalidomide, and dexamethasone (DRD), an active regimen in the treatment of sirolimus-associated plasmablastic lymphoma (PBL) in the setting of Gorham's lymphangiomatosis: a case report","volume":"20","author":"Lee","year":"2020","journal-title":"Clin Lymph Myelom Leuke"},{"issue":"24","key":"10.1016\/j.clml.2025.05.024_bib0063","first-page":"6069","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood","volume":"113","author":"Dunleavy","year":"2009","journal-title":"J Am Soc Hematol"},{"issue":"10","key":"10.1016\/j.clml.2025.05.024_bib0064","first-page":"1699","article-title":"Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas","volume":"18","author":"An","year":"2004","journal-title":"Leukemia"},{"issue":"29","key":"10.1016\/j.clml.2025.05.024_bib0065","first-page":"13069","article-title":"Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma","volume":"107","author":"Sarosiek","year":"2010","journal-title":"Proceed Nat Acad Sci"},{"key":"10.1016\/j.clml.2025.05.024_bib0066","first-page":"12","article-title":"Bortezomib in plasmablastic lymphoma: a glimpse of hope for a hard-to-treat disease","volume":"62","author":"Guerrero-Garcia","year":"2017","journal-title":"Leuke Res"},{"issue":"1","key":"10.1016\/j.clml.2025.05.024_bib0067","first-page":"85","article-title":"Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1","volume":"30","author":"Montes-Moreno","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2025.05.024_bib0068","first-page":"967","article-title":"Refractory plasmablastic lymphoma\u2014a review of treatment options beyond standard therapy","volume":"96","author":"Pretscher","year":"2017","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.clml.2025.05.024_bib0069","first-page":"e197","article-title":"Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia","volume":"31","author":"Holderness","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.05.024_bib0070","article-title":"Interleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targets","volume":"7","author":"Mine","year":"2017","journal-title":"Sci Rep"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:08:28Z","timestamp":1758604108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":70,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2152265025001971"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.024","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasmablastic Lymphoma\u2014A Crosstalk Between Myeloma and Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}